<DOC>
	<DOCNO>NCT01443845</DOCNO>
	<brief_summary>To demonstrate additional benefit roflumilast add fixed-dose combination ( FDC ) LABA/ICS reduction exacerbation subject severe severe COPD .</brief_summary>
	<brief_title>Roflumilast Chronic Obstructive Pulmonary Disease ( COPD ) Patients Treated With Fixed Dose Combinations Long-acting β2-agonist ( LABA ) Inhaled Corticosteroid ( ICS )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<criteria>1 . Male female patient least 40 year age 2 . History COPD ( accord Global Initiative Chronic Obstructive Lung Disease [ GOLD ] 2010 ) least 12 month prior Screening ( Visit 1 ) associate chronic productive cough 3 month 2 consecutive year ( cause productive cough exclude ) . Only patient chronic bronchitis include ( concomitant emphysema permit ) 3 . Forced expiratory volume 1 second ( FEV1 ) /forced vital capacity ( FVC ) ratio ( postbronchodilator ) &lt; 70 % Screening ( Visit 1 ) 4 . FEV1 ( postbronchodilator ) ≤ 50 % predict Screening ( Visit 1 ) 5 . At least two documented moderate severe COPD exacerbation within 12 month prior Screening ( Visit 1 ) 6 . Patients must FDC LABA/ICS treatment ≥ 3 month prior Screening ( Visit 1 ) 7 . Former smoker ( define smoke cessation least 1 year ago ) current smoker ( include patient cease smoke within past year ) smoke history least 20 packyears 1 . Moderate severe COPD exacerbation and/or COPD exacerbation treat antibiotic systemic glucocorticosteroids within 4 week Screening ( Visit 1 ) ( ie , patient must clinically stable ) 2 . Known alpha1antitrypsin deficiency 3 . Current diagnosis asthma ( either control uncontrolled ) ( Note : History childhood asthma exclusionary . ) 4 . Body mass index ( BMI ) ≥ 45 kg/m2 5 . Patients history ( within 5 year ) current diagnosis cancer basal squamous cell skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Exacerbations</keyword>
	<keyword>Roflumilast</keyword>
	<keyword>Daliresp</keyword>
</DOC>